STOCK TITAN

[Form 4] Quanterix Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4

Quanterix Corp (QTRX) insider purchase by CFO: The filing shows Sriram Vandana, Chief Financial Officer, acquired 4,150 shares of Quanterix common stock on 09/12/2025 at $4.79 per share. After the transaction Vandana beneficially owned 87,200 shares in total, which the filing notes includes 72,447 restricted stock units. The Form 4 was submitted with a signature executed by an attorney-in-fact on 09/15/2025. The document records a single non-derivative purchase and lists no derivative transactions or additional amendments.

Quanterix Corp (QTRX) insider purchase da parte del CFO: la dichiarazione mostra che Sriram Vandana, Chief Financial Officer, ha acquistato 4.150 azioni ordinarie di Quanterix il 12/09/2025 a 4,79 $ per azione. Dopo la transazione Vandana possedeva beneficiariamente in totale 87.200 azioni, inclusi 72.447 unità di azioni vincolate. Il modulo Form 4 è stato presentato con una firma eseguita da un procuratore il 15/09/2025. Il documento registra un singolo acquisto non derivativo e non segnala transazioni derivate né emendamenti aggiuntivi.
Quanterix Corp (QTRX) compra insider por parte del CFO: El registro muestra que Sriram Vandana, Director financiero (CFO), adquirió 4.150 acciones comunes de Quanterix el 12/09/2025 a 4,79 $ por acción. Tras la operación Vandana poseía de manera beneficiosa 87.200 acciones en total, que la declaración señala incluye 72.447 unidades de acciones restringidas. El Formulario 4 se presentó con una firma realizada por apoderado el 15/09/2025. El Formulario 4 registra una única compra no derivativa y no lista transacciones derivadas ni enmiendas adicionales.
퀀터릭스 코프(QTRX) 내부자 매수 CFO: 공시에는 CFO인 시라람 반다나가 2025년 9월 12일 주당 4.79달러로 Quanterix 일반주 4,150주를 취득했다고 나와 있습니다. 거래 후 반다나는 총 87,200주를 이익상 보유했고, 공시에는 72,447주 제한주식 유닛이 포함되어 있다고 기록되어 있습니다. 4폼은 2025년 9월 15일 대리인에 의해 서명이 실행된 상태로 제출되었습니다. 문서는 비파생 매수 한 건만 기록하고 파생 거래나 추가 개정사항은 목록에 없습니다.
Quanterix Corp (QTRX) achat d’initié par le CFO: Le dépôt indique que Sriram Vandana, directeur financier (CFO), a acquis 4 150 actions ordinaires de Quanterix le 12/09/2025 à 4,79 $ par action. Après la transaction, Vandana détenait bénéficiairement au total 87 200 actions, ce que le dépôt mentionne inclure 72 447 unités d’actions restreintes. Le Formulaire 4 a été soumis avec une signature exécutée par un mandataire le 15/09/2025. Le document enregistre un seul achat non dérivé et ne mentionne aucune transaction dérivée ni amendement supplémentaire.
Quanterix Corp (QTRX) Insiderkauf durch CFO: Die Einreichung zeigt, dass Sriram Vandana, Chief Financial Officer, am 12.09.2025 4.150 Stammaktien von Quanterix zu 4,79 $ pro Aktie erworben hat. Nach der Transaktion war Vandana insgesamt 87.200 Aktien vorteilhafter besessen, wozu laut der Einreichung 72.447 Restricted-Stock-Units gehören. Das Formular 4 wurde mit einer von einem Bevollmächtigten ausgeführten Unterschrift am 15.09.2025 eingereicht. Das Dokument verzeichnet einen einzelnen nicht derivativen Kauf und listet keine derivativen Transaktionen oder weiteren Änderungen auf.
شراء داخلي في Quanterix Corp (QTRX) من قِبل المدير المالي: يظهر الإيداع أن سورام فندانّا، المدير المالي، اشترى 4,150 سهماً عاديًا من Quanterix في 12/09/2025 بسعر 4.79 دولار للسهم. بعد الصفقة امتلك فندانّا بشكل مستفيد 87,200 سهماً بإجمالها، والتي ذكرها الإيداع وتضم 72,447 وحدة أسهم مقيدة. تم تقديم النموذج 4 بتوقيع نفذه وكيل بموجب تفويض في 15/09/2025. يسجل المستند شراءاً واحداً غير مشتق ولا يدرج أية معاملات مشتقة أو تعديلات إضافية.
Quanterix Corp (QTRX) 内幕购买:CFO 操作记录显示,Sriram Vandana(首席財务官)在 2025-09-12 以每股 4.79 美元购买了 4,150 股 Quanterix 普通股。交易后,Vandana 持有的受益所有权总计 87,200 股,其中包括 72,447 股受限股票单位。Form 4 表格于 2025-09-15 由代理人签署后提交。该文件记录了一笔单一的非衍生性购买,未列出任何衍生交易或额外修订。
Positive
  • CFO purchase disclosed, showing transparency in insider activity
  • Post-transaction ownership specified (87,200 shares) with breakdown including restricted stock units
  • Filing includes required details (date, price, amount) consistent with Section 16 reporting
Negative
  • No information on total outstanding shares provided, so transaction materiality cannot be determined from this filing alone

Insights

TL;DR: Company CFO purchased 4,150 shares at $4.79, increasing reported beneficial ownership to 87,200 shares.

The trade is a straightforward, non-derivative acquisition by the Chief Financial Officer. The filing discloses the total post-transaction ownership and explicitly states that 72,447 of the reported shares are restricted stock units, clarifying the composition of beneficial ownership. There are no derivative transactions reported and no amendments noted. From a market-impact perspective the filing does not quantify the transaction relative to outstanding shares, so materiality to shareholders cannot be assessed from this form alone.

TL;DR: Routine insider purchase disclosure showing RSU holdings; filing appears compliant and complete for reported items.

The Form 4 identifies the reporting person, role (CFO), relationship to the issuer, transaction date, price, and resulting beneficial ownership, and includes an explanatory note about restricted stock units. The signature was provided via attorney-in-fact as permitted. The filing contains the required data fields for a Section 16 report and reports no dispositions or derivative activity. It presents no governance red flags based solely on the disclosed entries.

Quanterix Corp (QTRX) insider purchase da parte del CFO: la dichiarazione mostra che Sriram Vandana, Chief Financial Officer, ha acquistato 4.150 azioni ordinarie di Quanterix il 12/09/2025 a 4,79 $ per azione. Dopo la transazione Vandana possedeva beneficiariamente in totale 87.200 azioni, inclusi 72.447 unità di azioni vincolate. Il modulo Form 4 è stato presentato con una firma eseguita da un procuratore il 15/09/2025. Il documento registra un singolo acquisto non derivativo e non segnala transazioni derivate né emendamenti aggiuntivi.
Quanterix Corp (QTRX) compra insider por parte del CFO: El registro muestra que Sriram Vandana, Director financiero (CFO), adquirió 4.150 acciones comunes de Quanterix el 12/09/2025 a 4,79 $ por acción. Tras la operación Vandana poseía de manera beneficiosa 87.200 acciones en total, que la declaración señala incluye 72.447 unidades de acciones restringidas. El Formulario 4 se presentó con una firma realizada por apoderado el 15/09/2025. El Formulario 4 registra una única compra no derivativa y no lista transacciones derivadas ni enmiendas adicionales.
퀀터릭스 코프(QTRX) 내부자 매수 CFO: 공시에는 CFO인 시라람 반다나가 2025년 9월 12일 주당 4.79달러로 Quanterix 일반주 4,150주를 취득했다고 나와 있습니다. 거래 후 반다나는 총 87,200주를 이익상 보유했고, 공시에는 72,447주 제한주식 유닛이 포함되어 있다고 기록되어 있습니다. 4폼은 2025년 9월 15일 대리인에 의해 서명이 실행된 상태로 제출되었습니다. 문서는 비파생 매수 한 건만 기록하고 파생 거래나 추가 개정사항은 목록에 없습니다.
Quanterix Corp (QTRX) achat d’initié par le CFO: Le dépôt indique que Sriram Vandana, directeur financier (CFO), a acquis 4 150 actions ordinaires de Quanterix le 12/09/2025 à 4,79 $ par action. Après la transaction, Vandana détenait bénéficiairement au total 87 200 actions, ce que le dépôt mentionne inclure 72 447 unités d’actions restreintes. Le Formulaire 4 a été soumis avec une signature exécutée par un mandataire le 15/09/2025. Le document enregistre un seul achat non dérivé et ne mentionne aucune transaction dérivée ni amendement supplémentaire.
Quanterix Corp (QTRX) Insiderkauf durch CFO: Die Einreichung zeigt, dass Sriram Vandana, Chief Financial Officer, am 12.09.2025 4.150 Stammaktien von Quanterix zu 4,79 $ pro Aktie erworben hat. Nach der Transaktion war Vandana insgesamt 87.200 Aktien vorteilhafter besessen, wozu laut der Einreichung 72.447 Restricted-Stock-Units gehören. Das Formular 4 wurde mit einer von einem Bevollmächtigten ausgeführten Unterschrift am 15.09.2025 eingereicht. Das Dokument verzeichnet einen einzelnen nicht derivativen Kauf und listet keine derivativen Transaktionen oder weiteren Änderungen auf.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Sriram Vandana

(Last) (First) (Middle)
C/O QUANTERIX CORPORATION
900 MIDDLESEX TURNPIKE

(Street)
BILLERICA MA 01821

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Quanterix Corp [ QTRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/12/2025 P 4,150 A $4.79 87,200(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Includes 72,447 restricted stock units.
Remarks:
/s/ Brian Keane, as Attorney-in-Fact 09/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Quanterix (QTRX) CFO Sriram Vandana report on Form 4?

The Form 4 reports that CFO Sriram Vandana acquired 4,150 shares of Quanterix common stock on 09/12/2025 at $4.79 per share.

How many Quanterix shares does the reporting person own after the transaction?

After the reported purchase the filing states the reporting person beneficially owned 87,200 shares, which includes 72,447 restricted stock units.

Were any derivative securities reported in this Form 4 for QTRX?

No. The Form 4 lists only a non-derivative purchase of common stock and shows no derivative transactions.

When was the Form 4 signed and who signed it?

The filing shows a signature executed by Brian Keane, as Attorney-in-Fact on 09/15/2025.

Does the Form 4 state whether the transaction was part of a plan or automatic sale/purchase program?

No such plan or automatic transaction designation is included in the provided content; the filing lists a single purchase with code P.
Quanterix

NASDAQ:QTRX

QTRX Rankings

QTRX Latest News

QTRX Latest SEC Filings

QTRX Stock Data

246.27M
43.46M
6.46%
73.43%
9.05%
Medical Devices
Laboratory Analytical Instruments
Link
United States
BILLERICA